since fabry disease is complex and rare, treatments are limited and typically revolve around introducing a synthetic version of the alpha-gal enzyme into the body to restore proper levels or undergoing oral chaperone therapy, which works by repairing alpha-gal enzymes within the body to help foster proper function and the breakdown of fatty substances.
fabry disease survival and treatments in canada
since there is no cure for fabry disease, treatment is the only option available for people with the faulty gene. in canada, the two mainstay therapies are mentioned above: enzyme replacement therapy and oral chaperone therapy. that said, some promising emerging therapies could help those with fabry disease in the near future. they include:
- substrate reduction therapy (srt)
- gene therapy
srt is an oral molecule drug that stops the biosynthesis of glycosphingolipids in the body. it’s designed to prevent the production of a substrate that encourages the accumulation of fats in the body. the second, gene therapy, involves introducing new genetic material into the body to fight off the disease.
with a lack of viable treatment options, people with fabry disease are often left to cope and deal with symptoms even while in active therapy. oral therapy using the drug migalastat, which was only approved for use in the late 2010s, is shown to be effective in just under half of people with fabry disease.
in people who receive ert, the odds of an improved quality of life are poorly understood. some
clinical studies
have seen marked improvement after ert with regression of heart disease, namely left ventricular hypertrophy. in contrast, other studies only show a small or no improvement with ert. others have even seen a worsening of the disease, with the walls of the heart thickening gradually over time with ert.